Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

e role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alfa), endocrine and cardiometabolic disorders (Glucophage(R), metformin); (Concor(R), bisoprolol); (Euthyrox(R), levothyroxine); (Saizen(R) and Serostim(R), somatropin). Not all products are available in all markets.

With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32,700 employees in 60 countries. Its success
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015   CSL Behring ... a Marketing Authorization Application (MAA) for the company,s ... IX with recombinant albumin (rIX-FP) for the prophylaxis ... Hemophilia B. Upon Swissmedic approval, rIX-FP will provide ... with dosing intervals up to 14 days. ...
(Date:7/28/2015)... July 28, 2015 Baebies, Inc. today announced ... $13 million. The oversubscribed round of financing included key ... Duke endowment), Cunning Capital, Triad, LLC, the Duke Angel ... Center. Many of Advanced Liquid Logic,s (ALL) former investors ... invested. "Rex is pleased to support ...
(Date:7/28/2015)... Fla. , July 28, 2015 ... Spectralink, the global leader in purpose-built wireless communications, ... (Bay Area Regional), a 104-bed acute-care facility in ... to implement the Voalte One™ solution on Spectralink ... "Since Spectralink named Voalte a member of ...
Breaking Medicine Technology:Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4Baebies, Inc. Raises $13 Million in Oversubscribed Round of Financing 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
(Date:7/28/2015)... ... ... Dr. Edward Buckingham and Buckingham Center for Facial Plastic Surgery, ... Coming to Austin from Philadelphia, Dr. Roy will be completing his Fellowship in facial ... annually by the American Academy of Facial Plastic and Reconstructive Surgery. , Since ...
(Date:7/28/2015)... ... 28, 2015 , ... DuPont leaders today joined public and ... more about the impact of U.S. collaborations with local partners under the U.S. ... development as an engine of broad-based economic growth in the region. , ...
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a leading global ... that enable the Internet of Things (IoT), announced its new medical panel PC, ... exceptional computing power and multitasking capabilities. The MLC 4-21 is completely fanless, and ...
(Date:7/28/2015)... ... 2015 , ... Dr. Aziz Ahmad recently gave a talk on the current ... 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center Large HR ... in colorectal surgery and has more than 35 years of experience in the surgical ...
(Date:7/28/2015)... ... ... Egg freezing is becoming an increasingly popular option for family ... Dr. Michael Kettel explained in an article from the San Diego Union-Tribune ... generations who had to make choices between their fertility and their career or personal ...
Breaking Medicine News(10 mins):Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3
... Buyout augments existing business in Philadelphia, New York ... in Tucson, Melbourne, Fla., and San Antonio, ... provider of care and care management services for,frail ... reached agreement,to acquire Care Level Management of Woodland ...
... million of required financing now in place ... - Bioniche Life Sciences,Inc. (TSX: BNC), a ... it has secured an amendment,to a pre-existing ... Office of Industry Canada that will support ...
... CHICAGO, June 25 In response to news reports ... is allegedly being treated,for medication use related to migraine, ... Migraine is not a daily headache and the use ... basis is not recommended., Pain killers are not ...
... KONG, June 25 /Xinhua-PRNewswire-FirstCall/ -- The Board ... "Company"; stock code:,8180.HK) is pleased to announce ... in entering China,s hospital management market through ... Limited and,Daopei Hospitals Group, the largest private ...
... stocked in nationwide pharmacies will provide easy access for ... ... (OTC,Bulletin Board: DSCI), a provider of advanced wound care products,announced today that ... has been cleared by the FDA for,over the counter (OTC) sales. This ...
... Executive,Director, Diana Fuentes-Michel today urged eligible nursing students ... college to immediately apply,for the 2007-08 academic year ... The deadline for applications is June 30, 2008., ... be aware of all available,resources to help them ...
Cached Medicine News:Health News:INSPIRIS Acquires Care Level Management 2Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 2Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 3Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 4Health News:National Headache Foundation Offers Statement, Experts on Appropriate Use of Medications for Migraine Treatment 2Health News:Golden Meditech Pioneers into China's Hospital Market 2Health News:Golden Meditech Pioneers into China's Hospital Market 3Health News:Golden Meditech Pioneers into China's Hospital Market 4Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 3Health News:Nursing Loan Forgiveness Programs -- More Applicants Needed by June 30, 2008 2
Volume: 5 ml; Volume Graduation: 1/10 ml...
... AlphaForce fills 25ml pipette in ... fatest setting. Rechargeable during use. ... all with variable speed including ... Autoclavable pipette holder. Low battery ...
Inquire...
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Medicine Products: